Price Alert

Entrada Therapeutics Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD

5.29

0.04 (0.76%)

At close: Aug 15, 2025, 3:59 PM

5.27

-0.28%

After-hours: Aug 15, 2025, 04:04 PM EDT

Entrada Therapeutics Statistics

Share Statistics

Entrada Therapeutics has 38.04M shares outstanding. The number of shares has increased by 2.03% in one year.

Shares Outstanding	38.04M
Shares Change (YoY)	2.03%
Shares Change (QoQ)	0.95%
Owned by Institutions (%)	52.23%
Shares Floating	22.41M
Failed to Deliver (FTD) Shares	27,000
FTD / Avg. Volume	16.02%

Short Selling Information

The latest short interest is 1.3M, so 3.42% of the outstanding shares have been sold short.

Short Interest	1.3M
Short % of Shares Out	3.42%
Short % of Float	6.32%
Short Ratio (days to cover)	8.94

Valuation Ratios

The PE ratio is 9.83 and the forward PE ratio is -1.18. Entrada Therapeutics's PEG ratio is -0.01.

PE Ratio	9.83
Forward PE	-1.18
PS Ratio	3.06
Forward PS	10.7
PB Ratio	1.5
P/FCF Ratio	-14.43
PEG Ratio	-0.01

Financial Ratio History

Enterprise Valuation

Entrada Therapeutics has an Enterprise Value (EV) of 603.02M.

EV / Sales	2.86
EV / EBITDA	12.83
EV / EBIT	-14.51
EV / FCF	-13.49

Financial Position

The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.14.

Current Ratio	11.15
Quick Ratio	11.15
Debt / Equity	0.14
Debt / EBITDA	1.26
Debt / FCF	-1.32
Interest Coverage	0

Financial Efficiency

Return on Equity is 15.31% and Return on Invested Capital is 9.39%.

Return on Equity	15.31%
Return on Assets	12.47%
Return on Invested Capital	9.39%
Revenue Per Employee	$1.15M
Profits Per Employee	$358.61K
Employee Count	183
Asset Turnover	0.4
Inventory Turnover	n/a

Taxes

Income Tax	859K
Effective Tax Rate	1.29%

Stock Price Statistics

The stock price has increased by -64.74% in the last 52 weeks. The beta is -0.13, so Entrada Therapeutics's price volatility has been lower than the market average.

Beta	-0.13
52-Week Price Change	-64.74%
50-Day Moving Average	6.92
200-Day Moving Average	11.75
Relative Strength Index (RSI)	30.53
Average Volume (20 Days)	168,559

Income Statement

In the last 12 months, Entrada Therapeutics had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.

Revenue	210.78M
Gross Profit	210.78M
Operating Income	47.01M
Net Income	65.63M
EBITDA	47.01M
EBIT	47.01M
Earnings Per Share (EPS)	1.76

Full Income Statement

Balance Sheet

The company has 101.21M in cash and 59.21M in debt, giving a net cash position of 42M.

Cash & Cash Equivalents	101.21M
Total Debt	59.21M
Net Cash	42M
Retained Earnings	-129.34M
Total Assets	448.78M
Working Capital	349.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -41.56M and capital expenditures -3.16M, giving a free cash flow of -44.72M.

Operating Cash Flow	-41.56M
Capital Expenditures	-3.16M
Free Cash Flow	-44.72M
FCF Per Share	-1.2

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 22.3% and 31.13%.

Gross Margin	100%
Operating Margin	22.3%
Pretax Margin	31.54%
Profit Margin	31.13%
EBITDA Margin	22.3%
EBIT Margin	22.3%
FCF Margin	-21.21%

Dividends & Yields

TRDA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	10.17%
FCF Yield	-6.93%

Dividend Details

Analyst Forecast

The average price target for TRDA is $28, which is 458.9% higher than the current price. The consensus rating is "Buy".

Price Target	$28
Price Target Difference	458.9%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	21.33
Graham Upside	325.75%

Scores

Altman Z-Score	1.52
Piotroski F-Score	1